Tevogen Bio (NASDAQ:TVGN) Trading Down 5.9% – Should You Sell?

Tevogen Bio Holdings Inc. (NASDAQ:TVGN)’s stock price dropped 5.9% during mid-day trading on Wednesday . The company traded as low as $8.00 and last traded at $8.14. Approximately 12,718 shares were traded during trading, a decline of 55% from the average daily volume of 28,398 shares. The stock had previously closed at $8.65.

Analysts Set New Price Targets

TVGN has been the topic of a number of recent research reports. Wall Street Zen cut Tevogen Bio to a “strong sell” rating in a research note on Saturday, March 21st. D. Boral Capital cut Tevogen Bio from a “buy” rating to a “hold” rating in a research note on Wednesday, March 4th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tevogen Bio in a research note on Monday. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Tevogen Bio has an average rating of “Reduce” and an average price target of $100.00.

Tevogen Bio Stock Performance

The stock’s fifty day moving average price is $7.94 and its two-hundred day moving average price is $17.15.

Institutional Trading of Tevogen Bio

A number of institutional investors have recently modified their holdings of the company. Deutsche Bank AG boosted its holdings in shares of Tevogen Bio by 304.1% during the fourth quarter. Deutsche Bank AG now owns 173,734 shares of the company’s stock worth $57,000 after purchasing an additional 130,738 shares during the period. Goldman Sachs Group Inc. boosted its holdings in shares of Tevogen Bio by 126.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 273,694 shares of the company’s stock worth $91,000 after purchasing an additional 152,572 shares during the period. Finally, Bridgeway Capital Management LLC boosted its holdings in shares of Tevogen Bio by 66.7% during the third quarter. Bridgeway Capital Management LLC now owns 82,500 shares of the company’s stock worth $65,000 after purchasing an additional 33,000 shares during the period.

About Tevogen Bio

Tevogen Bio plc (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company’s lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML).

In addition to its lead program in AML, Tevogen Bio’s pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections.